A Clinical Trial Investigating the Short-term Relief of Symptoms of Acute Pharyngitis by Treatment With Three Different Doses of MYRAMISTIN™ Oromucosal Spray

Exclusion Criteria

• •1. Patients with strong suspicion of Group A streptococcus infection. Either swab test is positive OR McIsaac Score ≥ 3 points
• •2. Presence of signs or symptoms of any acute infection for which treatment with antibiotics is mandatory and/or should not be postponed; i.e. accompanied fever (\> 38°C at Visit 1) and/or - if visually identified pharyngeal - presence of seropurulent, purulent, fibro serous or fibrinous exudate from the pharyngeal mucosa
• •3. Patients with allergies or bronchial asthma who have a history of exacerbations within 30 days prior to trial inclusion
• •4. The use of any systemic analgesics / local analgesics in the throat area (e.g. Acetyl Salicylic Acid = ASA \> 100 mg) during the trial or within 12 hours prior first study medication application. Exception Paracetamol: intake of Paracetamol is allowed up to 6 hours before first application of IMP
• •5. The use of systemic antibiotics / local antibiotics in the throat area during the trial and within the previous 7 days prior to Visit 1
• •6. The use of any systemic or local (i.e. in the throat area) antihistamines started within 2 weeks prior to Visit 1
• •7. The use of any systemic anti-inflammatory drug / local anti-inflammatory drug in the throat area (e.g. non-steroidal anti- inflammatory drugs or glucocorticoids) during the trial or within 12 hours prior to first IMP application
• •8. The use of local anaesthetics for treatment of sore throat during the trial or within 12 hours prior to first IMP application
• •9. The use of any other 'sore throat medication' (e.g. lozenges, drops, sprays, decongestants) or other 'cold medication' that could interfere the trial results within the previous 12 hours prior to first study medication application
• •10. Major wounds of the mouth and throat
• •11. Immunodeficiency disorders (e.g. organ transplantation, HIV infection)
• •12. Existing cardiac, haematological, hepatic, renal, gastrointestinal, metabolic and / or pathological findings, which might interfere with the drug's safety, tolerability and / or absorption according to the judgement of the Investigator
• •13. Any neurological or psychiatric conditions, which might give the impression that the patients will not comply with the protocol and trial needs
• •14. Patients with history (previous 5 years) or present condition of any malignancy
• •15. Known hypersensitivity to any ingredient of MyramistinTM
• •16. Previous participation in the trial
• •17. Parallel participation in any other trial during the previous 90 days before screening
• •18. History of alcohol or drug abuse
• •19. Known or suspected of being unable to comply with the clinical trial protocol (e.g. no permanent address, history of drug abuse, known to be non-compliant or presenting an unstable psychiatric history)
• •20. Legal incapacity and / or other circumstances rendering the patients